1. Home
  2. FPI vs MLYS Comparison

FPI vs MLYS Comparison

Compare FPI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Farmland Partners Inc.

FPI

Farmland Partners Inc.

HOLD

Current Price

$9.72

Market Cap

448.2M

Sector

Real Estate

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$37.07

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FPI
MLYS
Founded
2013
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
448.2M
3.1B
IPO Year
2014
2023

Fundamental Metrics

Financial Performance
Metric
FPI
MLYS
Price
$9.72
$37.07
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$47.33
AVG Volume (30 Days)
543.5K
1.5M
Earning Date
10-29-2025
02-11-2026
Dividend Yield
2.47%
N/A
EPS Growth
296.76
N/A
EPS
1.27
N/A
Revenue
$52,990,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.62
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.37
$8.24
52 Week High
$12.87
$47.65

Technical Indicators

Market Signals
Indicator
FPI
MLYS
Relative Strength Index (RSI) 40.17 43.16
Support Level $9.73 $36.50
Resistance Level $9.87 $38.23
Average True Range (ATR) 0.16 1.68
MACD -0.03 0.09
Stochastic Oscillator 5.17 41.96

Price Performance

Historical Comparison
FPI
MLYS

About FPI Farmland Partners Inc.

Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: